Zai Lab Ltd (ZLAB) stock
ZLABNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30471% above fair value
$24.60−1.44 (-5.53%)
Close on Nov 13, 2026Market cap $3.82BP/E –Yield –
Zai Lab ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Zai Lab's ebitda for the twelve months ending Sep 30, 2026 was -$261.81M. For fiscal 2025 it was -$214.42M. The highest annual figure on record is -$50.84M in fiscal 2017.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$214.42M | – |
| FY2024 | Dec 31, 2024 | -$270.26M | – |
| FY2023 | Dec 31, 2023 | -$357.54M | – |
| FY2022 | Dec 31, 2022 | -$396.13M | – |
| FY2021 | Dec 31, 2021 | -$693.58M | – |
| FY2020 | Dec 31, 2020 | -$297.16M | – |
| FY2019 | Dec 31, 2019 | -$199.43M | – |
| FY2018 | Dec 31, 2018 | -$140.12M | – |
| FY2017 | Dec 31, 2017 | -$50.84M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$58.57M | – |
| Q2 FY2026 | Jun 30, 2026 | -$72.32M | – |
| Q1 FY2026 | Mar 31, 2026 | -$65.44M | – |
| Q4 FY2025 | Dec 31, 2025 | -$65.49M | – |
| Q3 FY2025 | Sep 30, 2025 | -$44.92M | – |
| Q2 FY2025 | Jun 30, 2025 | -$51.16M | – |
| Q1 FY2025 | Mar 31, 2025 | -$52.85M | – |
| Q4 FY2024 | Dec 31, 2024 | -$64.86M | – |
| Q3 FY2024 | Sep 30, 2024 | -$64.98M | – |
| Q2 FY2024 | Jun 30, 2024 | -$73.12M | – |
| Q1 FY2024 | Mar 31, 2024 | -$67.30M | – |
| Q4 FY2023 | Dec 31, 2023 | -$121.52M | – |
| Q3 FY2023 | Sep 30, 2023 | -$81.65M | – |
| Q2 FY2023 | Jun 30, 2023 | -$87.51M | – |
| Q1 FY2023 | Mar 31, 2023 | -$66.87M | – |
| Q4 FY2022 | Dec 31, 2022 | -$95.17M | – |
| Q3 FY2022 | Sep 30, 2022 | -$126.36M | – |
| Q2 FY2022 | Jun 30, 2022 | -$96.86M | – |
| Q1 FY2022 | Mar 31, 2022 | -$77.75M | – |
| Q4 FY2021 | Dec 31, 2021 | -$217.32M | – |
| Q3 FY2021 | Sep 30, 2021 | -$81.57M | – |
| Q2 FY2021 | Jun 30, 2021 | -$169.04M | – |
| Q1 FY2021 | Mar 31, 2021 | -$225.64M | – |
| Q4 FY2020 | Dec 31, 2020 | -$93.87M | – |
| Q3 FY2020 | Sep 30, 2020 | -$75.11M | – |
| Q2 FY2020 | Jun 30, 2020 | -$82.93M | – |
| Q1 FY2020 | Mar 31, 2020 | -$45.25M | – |
| Q4 FY2019 | Dec 31, 2019 | -$50.76M | – |
| Q3 FY2019 | Sep 30, 2019 | -$64.35M | – |
| Q4 FY2018 | Dec 31, 2018 | -$66.04M | – |
See a number that looks wrong?